CIBMTR

According to a recent study, nearly 100% of people said that it’s very important that researchers ask patients directly about their quality of life. Read more: cibmtr.org/Files/Patien...

Attending #ISOQOL 2025 this fall? A symposium will feature CIBMTR, highlighting the integration of PROs into clinical registries for HCT and cellular therapy, including HCT and CAR-T. Learn more: cibmtr.org/CIBMTR/About...

CIBMTR's August Newsletter is now available! Read about two new Scientific Directors, a PRO Protocol milestone, our newest Page Scholars, our CRO Services, and much more! Read online: cibmtr.org/CIBMTR/About...

New CIBMTR Scientific Director: Wasay Khan, MD, to serve as Scientific Director for Clinical Informatics. Read more about this exciting announcement: cibmtr.org/CIBMTR/About...

Health Care Providers: Have you ever wondered about the effects of CAR T-cells on your patients' #fertility? Help The Leukemia & Lymphoma Society gather critical information by referring patients to this survey: form.typeform.com/to/rGw4Udaj

We welcome our newest Page Scholars and congratulate our inaugural group of scholars! Read more about these two wonderful groups: cibmtr.org/CIBMTR/About...

Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR Allogeneic hematopoietic cell transplantation (HCT) remains a curative therapy for many patients with hematologic malignancies, bone marrow failure sy…

Just Published in Transplantation and Cellular Therapy Journal: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Read more: www.sciencedirect.com/science/arti...

After a partially matched transplant, #GVHD can result. Previously, partially matched donors caused more GVHD than fully matched donors in cancer patients. A new approach, using cyclophosphamide, can prevent most GVHD. Read more: cibmtr.org/Files/Patien...

New CIBMTR Scientific Director: Najla El Jurdi, MD, to serve as Scientific Director of Graft-versus-Host Disease Working Committee. Read more about this exciting announcement: cibmtr.org/CIBMTR/About...

NEW study results just published in the Journal of Clinical Oncology: Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis Following Mismatched Unrelated Donor PBSC Transplantation. Read more: ascopubs.org/doi/10.1200/...

In the past, people with sickle cell disease could only get #BMT if they had a fully matched donor, but with newer medicines, people can get BMT from a half-matched donor, like a parent or sibling. Read more about this BMT CTN study: cibmtr.org/Files/Patien...

A small BMT CTN study showed that #BMT is one good option for treating sickle cell disease in teens and young adults. Learn more about this study: cibmtr.org/Files/Patien...

CIBMTR is excited to announce we reached a major milestone on the CIBMTR PRO Protocol! More than 5,000 patient-reported outcomes (#PRO) surveys have now been collected from 1,700+ patients across 43 centers. Read more: cibmtr.org/CIBMTR/About...

Celebrating @cibmtr.bsky.social Dr Mary Horowitz as honorary chair of the @nmdp-org.bsky.social recognizing the transformational contributions she has made to the field of stem cell transplantation and to improved outcomes for our patients. She has also been a mentor to many of us.

CIBMTR's May Newsletter is now available! Read a message from our Advisory Committee Chair, a tribute to a leader in our field, about how to access our latest Summary Slides, about two of our working committees, and more. Read online: cibmtr.org/CIBMTR/About...

NOW AVAILABLE: 2024 CIBMTR Summary Slides. These slides provide an annual report on data submitted by US centers to CIBMTR, detailing practices and general survival outcomes following cellular therapies. Learn more: cibmtr.org/CIBMTR/Resou...

Results of a new BMT CTN study show that patients who got cyclophosphamide lived longer without CGVHD, compared to patients who got other medicines. Read more: cibmtr.org/Files/Patien...

Attending #EBMT25 beginning this weekend? Make sure to check out CIBMTR's abstracts. You can view the full list, here: cibmtr.org/Files/Meetin...

JOB POSTING: CIBMTR is seeking a part time (0.1 FTE) Scientific Director to co-lead our Immunobiology Working Committee. Learn more about this important position, here: cibmtr.org/Files/Career...